Anfinsen's principle (1961) showed that a protein's native structure is the global free-energy minimum — the sequence determines the fold. The corollary: misfolding is what produces Alzheimer's amyloid, prion diseases, and most neurodegenerative conditions.
A folded protein achieves its functional shape because evolution selected sequences whose lowest-energy configuration matches the required function. Misfolding can produce stable aggregates (amyloid plaques) that resist clearance and accumulate. Alpha-synuclein in Parkinson's, beta-amyloid in Alzheimer's, PrPSc in prion diseases — all share the structural-misfolding signature. Modern drug development increasingly targets the misfolding process itself.